Atrial Fibrillation Clinical Trial
— AntiAFibOfficial title:
Evaluating Changes in Epigenetic Methylation From Antiorbital Ionic Calcium in Adults With Atrial Fibrillation
The purpose of this study is to determine the mechanistic effects of an ionic calcium supplement in adults with atrial fibrillation. The study aims to determine if ionic calcium supplementation affects quality of life, rate of biological aging, fibrillation frequency, bone densitometry, and blood biomarkers of bone metabolism over a six month period compared to non-ionic calcium comparator supplement.
Status | Not yet recruiting |
Enrollment | 104 |
Est. completion date | June 2023 |
Est. primary completion date | December 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 70 Years |
Eligibility | Inclusion Criteria: - ? Adults 18-70 years of age - Active diagnosis of non-valvular atrial fibrillation - including paroxysmal, persistent, or long-standing persistent AF with typical electrocardiographic characteristics (i.e., absence of identifiable p-waves with irregularly irregular ventricular rate) without known complications, heart disease, or congenital heart defects (e.g., rapid ventricular rate, recent myocardial infarction, heart failure, stroke, cardiomyopathy, etc.) and/or with a formal diagnosis from a healthcare professional. - A European Heart Rhythm Association (EHRA) score greater than 1 (i.e., mild symptoms, normal daily activity not affected). - On a stable dose of all medications prior to study entry (i.e., consistent dose for a minimum of three months) - Willing to be randomized to take daily ionized calcium as a dietary supplement or placebo over the 24-week study period - On a stable dose of dietary supplements for at least one month prior to enrollment - Willing to avoid initiation of new supplements and/or medications unless otherwise indicated by a healthcare professional - Willing to have blood drawn on 6 occasions, and fast for 10-12 hours before blood draws, over the study period - Able to communicate via email, complete computer-administered questionnaires, and to read and write in English. - Must be able to provide written informed consent - Non-smokers (including tobacco and cannabis products, combusted or vaporized) - Approved to be eligible for study participation at the discretion of the Principal Investigators, after review of the Formal Eligibility Screen results. - Willing to avoid taking dietary supplements containing the following ingredients for the 24 weeks of study involvement: additional supplemental calcium in any form, vitamin D, vitamin K, selenium, magnesium, or zinc. Exclusion Criteria: - ? Individuals with a current or past diagnosis of permanent AF - Individuals with any thyroid or parathyroid disorders, or current use of thyroid medication for any reason. - Individuals with chronic kidney or liver disease, cancer, colorectal disease, and "other rare disorders". - Individuals with a current diagnosis of Congestive Heart Failure (CHF). - Individuals with a current or past diagnosis of Traumatic Brain Injury (TBI) or Cerebrovascular Accident (CVA)/Stroke. - Use of dihydropyridine or non-dihydropyridine calcium channel blockers for any reason - Not on a stable dose of anti-coagulant or anti-platelet prescription medications (i.e., consistent dose for a minimum of three months) - CHA2DS2-VASC score of = 2 and NOT on a stable dose (i.e. stable for at least 3 months) of oral anti-coagulant medication/therapy. - HAS-BLED score = 3 - Abnormalities in coagulation studies (e.g., INR = 2 or = 3.0) or hypercalcemia at the clinical screening visit. - Blood pressure = 140/90 mmHg at the clinical screening visit. - Current involvement or within 14 days prior to screening of a significant diet or weight loss program (such as NutriSystem, Jenny Craig, Atkin's or other low-carb diet programs) or very low-calorie liquid diet programs (such as Optifast, Medifast, and/or HMR) - Hospitalization (for any reason other than a scheduled medical procedure unrelated to AF) within 3 months prior to screening - Cardiac surgery within 3 months prior to screening - Malignancy within the last 5 years (with the exception of basal cell carcinoma, squamous cell carcinoma, and/or carcinoma in situ of the cervix) - Women who are lactating, pregnant or planning pregnancy within the next six months - Intake of = 2 standardized alcohol-containing beverages per day, 14 per week, or =4 in any single day within the past 14 days. - Women of child-bearing age, who are sexually active and are unwilling to use an appropriate form of contraception during the duration of the trial. - Smoking tobacco or nicotine products (combusted or vaporized) - Use of illicit drugs/substances (such as but not limited to cocaine, phencyclidine (PCP), and methamphetamine) within 14 days of screening - Currently participating in another interventional research study, or participated in another interventional research study within 14 days of screening - Do not have an active primary care provider or specialist (i.e., cardiologist) managing their atrial fibrillation - Current use of: dietary supplements or medications utilized for chelation purposes (i.e., ethylenediaminetetraacetic acid; EDTA), or of chemotherapeutic agents. - Allergy to corn |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
National University of Natural Medicine |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Frequency of Fibrillation Episodes | Kardia Mobile single lead ECG to measure fibrillation episodes; means over 1 week will be collected. | Week 12 | |
Other | Frequency of Fibrillation Episodes | Kardia Mobile single lead ECG to measure fibrillation episodes; means over 1 week will be collected. | Week 24 | |
Other | Coronary Artery Calcium Score | Composite CAC Score | Week 12 | |
Other | Coronary Artery Calcium Score | Composite CAC Score | Week 24 | |
Other | DEXA Bone Densitometry | Bone density T score resulting from DEXA | Week 12 | |
Other | DEXA Bone Densitometry | Bone density T score resulting from DEXA | Week 24 | |
Other | Ultrasonometer Bone Densitometry | Bone density T score resulting from ultrasound | Week 12 | |
Other | Ultrasonometer Bone Densitometry | Bone density T score resulting from ultrasound | Week 24 | |
Other | Activated Partial Thromboplastin Time | Measure of blood coagulation | Week 2 | |
Other | Activated Partial Thromboplastin Time | Measure of blood coagulation | Week 6 | |
Other | Activated Partial Thromboplastin Time | Measure of blood coagulation | Week 12 | |
Other | Activated Partial Thromboplastin Time | Measure of blood coagulation | Week 24 | |
Other | Prothrombin Time and Internationalized Normalized Ratio | Measure of blood coagulation | Week 2 | |
Other | Prothrombin Time and Internationalized Normalized Ratio | Measure of blood coagulation | Week 6 | |
Other | Prothrombin Time and Internationalized Normalized Ratio | Measure of blood coagulation | Week 12 | |
Other | Prothrombin Time and Internationalized Normalized Ratio | Measure of blood coagulation | Week 24 | |
Other | Thrombin Time | Measure of blood coagulation | Week 2 | |
Other | Thrombin Time | Measure of blood coagulation | Week 6 | |
Other | Thrombin Time | Measure of blood coagulation | Week 12 | |
Other | Thrombin Time | Measure of blood coagulation | Week 24 | |
Other | Concentration of Serum Calcium (ionic) | Measure of non-protein bound calcium concentration in the serum | Week 12 | |
Other | Concentration of BUN (serum) | Measure of renal function and protein turnover | Week 2 | |
Other | Concentration of BUN (serum) | Measure of renal function and protein turnover | Week 6 | |
Other | Concentration of BUN (serum) | Measure of renal function and protein turnover | Week 12 | |
Other | Concentration of BUN (serum) | Measure of renal function and protein turnover | Week 24 | |
Other | Concentration of Creatinine (serum) | Measure of renal function | Week 2 | |
Other | Concentration of Creatinine (serum) | Measure of renal function | Week 6 | |
Other | Concentration of Creatinine (serum) | Measure of renal function | Week 12 | |
Other | Concentration of Creatinine (serum) | Measure of renal function | Week 24 | |
Other | Glomerular Filtration Rate, estimated (eGFR) | Measure of renal function | Week 2 | |
Other | Glomerular Filtration Rate, estimated (eGFR) | Measure of renal function | Week 6 | |
Other | Glomerular Filtration Rate, estimated (eGFR) | Measure of renal function | Week 12 | |
Other | Glomerular Filtration Rate, estimated (eGFR) | Measure of renal function | Week 24 | |
Other | Concentration of Alanine aminotransferase (serum) | Measure of liver function | Week 2 | |
Other | Concentration of Alanine aminotransferase (serum) | Measure of liver function | Week 6 | |
Other | Concentration of Alanine aminotransferase (serum) | Measure of liver function | Week 12 | |
Other | Concentration of Alanine aminotransferase (serum) | Measure of liver function | Week 24 | |
Other | Concentration of Aspartate aminotransferase (serum) | Measure of liver function | Week 2 | |
Other | Concentration of Aspartate aminotransferase (serum) | Measure of liver function | Week 6 | |
Other | Concentration of Aspartate aminotransferase (serum) | Measure of liver function | Week 12 | |
Other | Concentration of Aspartate aminotransferase (serum) | Measure of liver function | Week 24 | |
Other | Concentration of Thyroid Stimulating Hormone | Measure of thyroid activity | Week 2 | |
Other | Concentration of Thyroid Stimulating Hormone | Measure of thyroid activity | Week 6 | |
Other | Concentration of Thyroid Stimulating Hormone | Measure of thyroid activity | Week 12 | |
Other | Concentration of Thyroid Stimulating Hormone | Measure of thyroid activity | Week 24 | |
Other | Concentration of Calcitonin | Measure of bone formation | Week 12 | |
Other | Concentration of Osteocalcin | Measure of bone formation | Week 12 | |
Other | Concentration of Bone-Specific Alkaline Phosphatase | Measure of bone turnover | Week 12 | |
Other | Concentration of Procollagen Type I Intact N Terminal Propeptide (PINP) | Measure of bone formation | Week 12 | |
Other | Concentration of Collagen Type I C-Telopeptide (CTx) | Measure of bone resorption | Week 12 | |
Primary | Rate of Biological Aging | Dunedin PACE objective measure of the rate of epigenetic aging | Week 12 | |
Primary | Rate of Biological Aging | Dunedin PACE objective measure of the rate of epigenetic aging | Week 24 | |
Secondary | Atrial fibrillation-specific health-related quality of life | Atrial Fibrillation Effect on QualiTy-of-life (AFEQT) Questionnaire | Week 12 | |
Secondary | Atrial fibrillation-specific health-related quality of life | Atrial Fibrillation Effect on QualiTy-of-life (AFEQT) Questionnaire | Week 24 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05654272 -
Development of CIRC Technologies
|
||
Completed |
NCT04571385 -
A Study Evaluating the Efficacy and Safety of AP30663 for Cardioversion in Participants With Atrial Fibrillation (AF)
|
Phase 2 | |
Terminated |
NCT04115735 -
His Bundle Recording From Subclavian Vein
|
||
Completed |
NCT05366803 -
Women's Health Initiative Silent Atrial Fibrillation Recording Study
|
N/A | |
Completed |
NCT02864758 -
Benefit-Risk Of Arterial THrombotic prEvention With Rivaroxaban for Atrial Fibrillation in France
|
||
Recruiting |
NCT05442203 -
Electrocardiogram-based Artificial Intelligence-assisted Detection of Heart Disease
|
N/A | |
Completed |
NCT05599308 -
Evaluation of Blood Pressure Monitor With AFib Screening Feature
|
N/A | |
Completed |
NCT03790917 -
Assessment of Adherence to New Oral anTicoagulants in Atrial Fibrillation patiEnts Within the Outpatient registrY
|
||
Enrolling by invitation |
NCT05890274 -
Atrial Fibrillation (AF) and Electrocardiogram (EKG) Interpretation Project ECHO
|
N/A | |
Recruiting |
NCT05316870 -
Construction and Effect Evaluation of Anticoagulation Management Model in Atrial Fibrillation
|
N/A | |
Recruiting |
NCT05266144 -
Atrial Fibrillation Patients Treated With Catheter Ablation
|
||
Not yet recruiting |
NCT06023784 -
The Impact of LBBAP vs RVP on the Incidence of New-onset Atrial Fibrillation in Patients With Atrioventricular Block
|
N/A | |
Recruiting |
NCT05572814 -
Transform: Teaching, Technology, and Teams
|
N/A | |
Recruiting |
NCT04092985 -
Smart Watch iECG for the Detection of Cardiac Arrhythmias
|
||
Completed |
NCT04087122 -
Evaluate the Efficiency Impact of Conducting Active Temperature Management During Cardiac Cryoablation Procedures
|
N/A | |
Completed |
NCT06283654 -
Relieving the Emergency Department by Using a 1-lead ECG Device for Atrial Fibrillation Patients After Pulmonary Vein Isolation
|
||
Recruiting |
NCT05416086 -
iCLAS™ Cryoablation System Post-Market Clinical Follow-up (PMCF) Study
|
N/A | |
Completed |
NCT05067114 -
Solutions for Atrial Fibrillation Edvocacy (SAFE)
|
||
Completed |
NCT04546763 -
Study Watch AF Detection At Home
|
||
Completed |
NCT03761394 -
Pulsewatch: Smartwatch Monitoring for Atrial Fibrillation After Stroke
|
N/A |